Elsevier

Transplantation Proceedings

Volume 33, Issues 1–2, February–March 2001, Pages 202-206
Transplantation Proceedings

Immunobiology and experimental transplantation: dendritic cells; co-stimulatory pathways; intracellular signaling
The role of CD154 (CD40-ligand) in costimulation

https://doi.org/10.1016/S0041-1345(00)01975-8Get rights and content

Section snippets

Anti-CD154 mAbS in transplantation graft acceptance

The CD154 protein was discovered by generating a murine mAb antibody 5c8 that inhibited the contact-dependent helper function of a T-cell line by binding to a novel 30-kD surface protein.1 Studies with 5c8 mAb revealed that CD154 was transiently expressed by activated CD4+ T cells1 (Fig 1). Although these discoveries stimulated a profound interest in identifying the counterreceptor for CD154 and exploring the role of CD154 in mediating help for non-B cells, the appreciation that anti-CD154

Biology of CD154 and its counterreceptor CD40

In parallel with the development of mAb anti-CD154 therapeutics has been substantial progress in understanding the structure and function of CD154 (the 5c8 Ag18, 19, 20) and its counterreceptor, CD40. Among the many new and important advances in this field, perhaps two general areas are the most significant for transplantation: first, how closely CD154 expression is regulated and how the transience of CD154 expression relates to “monogamy;” second, how broadly CD40 is expressed and how CD40

Role of TRAF-3 in CD40 signaling

The understanding of CD40 signaling is another area of considerable interest that has the potential to yield fundamentally new modalities to facilitate graft acceptance. TRAF-3 was identified as a cytoplasmic signaling molecule that interacts with the cytoplasmic tails of CD40 and certain other tumor necrosis factor receptor (TNF-R) family members.34, 35, 36, 37 Although understanding of the role of TRAF-3 in signaling is still evolving, TRAF-3 gene products are known to participate in

Conclusion

Progress in the evaluation of anti-CD154 mAbs as therapeutics for graft acceptance has validated the CD154/CD40 pathway as a target for therapeutic intervention. Refinements in therapeutics could derive from understanding the ordered sequence by which CD4+ T helper cells activate appropriate APC to express costimulatory factors which result in T-cell clonal expansion and differentiation into effector cells. The CD40 signaling pathway provides additional avenues for rational therapeutic

First page preview

First page preview
Click to open first page preview

References (50)

  • A.A Rossini et al.

    Cell Transplant

    (1996)
  • L.R Covey et al.

    Mol Immunol

    (1994)
  • K.M Fries et al.

    Clin Immunol Immunopathol

    (1995)
  • A.C Fluckiger et al.

    Blood

    (1992)
  • H.M Hu et al.

    J Biol Chem

    (1994)
  • G Mosialos et al.

    Cell

    (1995)
  • T Sato et al.

    FEBS Lett

    (1995)
  • Y Xu et al.

    Immunity

    (1996)
  • W.G van Eyndhoven et al.

    Mol Immunol

    (1998)
  • W.G van Eyndhoven et al.

    Mol Immunol

    (1999)
  • M Takeuchi et al.

    J Biol Chem

    (1996)
  • R Brink et al.

    J Biol Chem

    (1998)
  • S Jiang et al.

    Hum Immunol

    (1998)
  • Z Liu et al.

    Hum Immunol

    (1999)
  • S Lederman et al.

    J Exp Med

    (1992)
  • P.S Russell et al.

    Annu Rev Med

    (1984)
  • P Kung et al.

    Science

    (1979)
  • P.C Kung et al.

    Vox Sang

    (1980)
  • A.B Cosimi et al.

    Transplant Proc

    (1981)
  • A.B Cosimi et al.

    N Engl J Med

    (1981)
  • T Uchiyama et al.

    J Immunol

    (1981)
  • T Uchiyama et al.

    J Immunol

    (1981)
  • T.A Waldmann et al.

    Am J Kidney Dis

    (1989)
  • R.P Junghans et al.

    Cancer Res

    (1990)
  • D.C Parker et al.

    Proc Natl Acad Sci USA

    (1995)
  • This work was supported by grants from the National Cancer Institute, NIH, and from Biogen Corporation, Cambridge, MA.

    View full text